We are excited to announce that o2h Ventures has been shortlisted as a finalist in the upcoming EISA 2020 Awards in the Best Newcomer category.
The category champions new entrants to the S/EIS market who are already making a significant impact.
Investing in seed stage companies covering novel drug discovery along with enabling services, tools and AI technologies, our human health EIS Fund is supporting innovation across UK life sciences. We have a track record of nurturing and investing into emerging life sciences and technology start-ups. The fund is in a unique position to offer investors access to innovative and potentially transformative seed stage start-ups.
For more information contact: email@example.com